DOCSLIB.ORG

Enrichment of Biologically Active Compounds from Selected Plants

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

TECHNISCHE UNIVERSITÄT MÜNCHEN

Lehrstuhl für Chemisch-Technische Analyse und Chemische Lebensmitteltechnologie

Enrichment of Biologically Active Compounds from Selected
Plants Using Adsorptive Bubble Separation

Leonor Thompson
Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für
Ernährung, Landnutzung und Umwelt der Technische Universität München zur Erlangung des akademischen Grades eines

Doktors der Naturwissenschaften (Dr. rer. nat.)

genehmigten Dissertation.

  • Vorsitzender:
  • Univ.-Prof. Dr. K. Sommer

1. Univ.-Prof. Dr. H. Parlar 2. Univ.-Prof. Dr. K.-H. Engel
Prüfer der Dissertation: Die Dissertation wurde am 16.06.2004 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 22.09.2004 angenommen.

Dedicated to the memory of my late father, for instilling in me the desire to learn and the praise for the good values of Life

Acknowledgements

The research work presented in this PhD thesis was realised at the Chair for Chemical and Technical Analysis and Chemical Food Technology of the Technical University of Munich, in Freising, Weihenstephan. I would like to express my gratitude to:

Prof. Dr. Harun Parlar, the Head of the Chair and my supervisor, for providing me with an interesting topic for the thesis, for the freedom to implement my ideas and the availability of funds for the financing of three years of work.

Dr. Mehmet Coelhan, the head of my working group, for providing that the required means for the pursuance of my work were met, for the practical hints, particularly in relation with the HPLC and GC-MS analysis, as well as the interesting discussions regarding chemistry.

Ms. Florence Beaume, for the good atmosphere in the laboratory, the interesting discussions on chemistry and themes other than science, for a great companionship during the time of hard work and sporadic pleasant breaks.

Dr. Carsten Wattenbach, for the help given with the NMR analysis and the readiness for the innumerable and challenging discussions concerning chemistry.

Mr. Albrecht Friess, for the kind, untiring and timely help in the improvement of the linguistics and presentation aspects of this thesis, as well as for sorting out administrative details of the thesis.

Mr. Kurt Sholz, for the prompt production of special glass apparatus for the Foam Fractionation.

Ms. Johanna Strohmeier, for the good atmosphere in the laboratory and companionship. Ms. Bettina Zimmerman, for the help with the GC-ECNI/MS analysis. Ms. Mareike Wenning from the Microbial Ecology Group, Technical University of Munich, for the help with the FTIR analysis.

Prof. Dr. Matthias Hamburger, Friedrich-Schiller University, Jena, for the kind supply of the tryptanthrin standard. The Raps Institute in Freising, Weihenstephan, the Thuringian State Institute for Agriculture, Thuringia and the firma BAFA, Malsch, for the kind supply of plant raw materials.

I finally express my deepest gratitude to my wonderful family to whom I owe so much: My mother Mrs. Lucia Thompson, for the support, encouragement, caring and for being a source of strength during the difficult moments. My siblings, in particular Prof. Dr. Rachael Thompson, Prof. Dr. Gertrude Thompson and Dr. Ricardo Thompson, for the support, encouragement, and wise advice.

My husband Dr. Michael Lutze, for helping with the linguistic improvement of this thesis, for always standing by me both for the happy and difficult moments, for the understanding, encouragement and loving. My small daughter Michelle Thompson Lutze, for being such a lovely child, a source of inspiration and for her contagious joy. Contents

______________________________________________________________________________

Contents

1. INTRODUCTION------------------------------------------------------------------------------ 1 2. THEORETICAL BACKGROUND ---------------------------------------------------- 5 2.1 Non-Foaming Adsorptive Bubble Separation and Foam Separation ------------------- 6 2.2 Foam Fractionation ------------------------------------------------------------------------------- 7
2.2.1 Adsorption ------------------------------------------------------------------------------------- 8 2.2.2 Foams ------------------------------------------------------------------------------------------13
2.2.2.2 Drainage and Thinning ---------------------------------------------------------------15 2.2.2.3 Gas Diffusion Coalescence and Bubble size---------------------------------------16 2.2.3.1 Foam Fractionation Devices ---------------------------------------------------------17
2.2.4 Efficiency of Foam Fractionation --------------------------------------------------------20 2.2.5 Parameters Influencing the Efficiency of Foam Fractionation---------------------22
2.2.5.1 Concentration of Solute and Surfactant-------------------------------------------22 2.2.5.2 Addition of Organic Solvents --------------------------------------------------------22 2.2.5.3 Addition of Electrolytes and Polyelectrolytes ------------------------------------23 2.2.5.4 Addition of Viscosity Enhancers ----------------------------------------------------23 2.2.5.5 pH of Solution---------------------------------------------------------------------------24 2.2.5.6 Ionic Strength---------------------------------------------------------------------------24 2.2.5.7 Gas Flow Rate --------------------------------------------------------------------------24 2.2.5.8 Height of Liquid Pool------------------------------------------------------------------25 2.2.5.9 Height of Foam Tower ----------------------------------------------------------------25 2.2.5.10 Internal Reflux Ratio ----------------------------------------------------------------25

2.3 Plant Materials Under Investigation----------------------------------------------------------26
2.3.1 Calendula Officinalis L. --------------------------------------------------------------------27
2.3.1.1 General-----------------------------------------------------------------------------------27 2.3.1.2 Chemical Composition ----------------------------------------------------------------28 2.3.1.3 Active Principles------------------------------------------------------------------------29 2.3.1.4 Other Components---------------------------------------------------------------------33 2.3.1.5 Biological and Pharmacological Activity ------------------------------------------34 2.3.1.6 Toxicology -------------------------------------------------------------------------------34

Contents

______________________________________________________________________________

2.3.2 Camellia Sinensis L.-------------------------------------------------------------------------35
2.3.2.1 General-----------------------------------------------------------------------------------35 2.3.2.2 Chemical Composition ----------------------------------------------------------------36 2.3.2.3 Active Principle-------------------------------------------------------------------------36 2.3.2.4 Other compounds ----------------------------------------------------------------------39
2.3.3 Isatis Tinctoria L. ----------------------------------------------------------------------------44
2.3.3.1 General-----------------------------------------------------------------------------------44 2.3.3.2 Chemical Composition ----------------------------------------------------------------45 2.3.3.3 Active Principle-------------------------------------------------------------------------45 2.3.3.5 Important Conversions of the Main Components -------------------------------46 2.3.3.6 Biological and Pharmacological Activity ------------------------------------------47 2.3.3.7 Toxicity-----------------------------------------------------------------------------------47
2.3.4 Cannabis Sativa L. --------------------------------------------------------------------------48
2.3.4.1 General-----------------------------------------------------------------------------------48 2.3.4.2 Chemical Composition ----------------------------------------------------------------49 2.3.4.3 Active Principle-------------------------------------------------------------------------50 2.3.4.4 Other components----------------------------------------------------------------------52 2.3.4.5 Important Reactions of Active Cannabinoids ------------------------------------52 2.3.4.6 Biological and Pharmacological Activity ------------------------------------------53 2.3.4.7 Toxicology -------------------------------------------------------------------------------54

3. MATERIALS EQUIPMENTS AND METHODS -------------------------------------------55 3.1 Materials -------------------------------------------------------------------------------------------55
3.1.1 Samples of Plant Materials ----------------------------------------------------------------55 3.1.2 Standards -------------------------------------------------------------------------------------56 3.1.3 Chemicals and Solvents--------------------------------------------------------------------58 3.1.4 Miscellaneous Materials--------------------------------------------------------------------59

3.2 Foam Fractionation Unit and Equipments --------------------------------------------------59
3.2.1 Foam Fractionation Unit-------------------------------------------------------------------59 3.2.2 High Performance Liquid Chromatography ------------------------------------------60 3.2.3 Gas Chromatography ----------------------------------------------------------------------61 3.2.3 UV-Vis Spectroscopy -----------------------------------------------------------------------61 3.2.4 Nuclear Magnetic Resonance Spectroscopy--------------------------------------------61

Contents

______________________________________________________________________________

3.2.5 Fourier Transform Infrared Microspectroscopy -------------------------------------61 3.2.6 Other Equipments---------------------------------------------------------------------------62

3.3 Methods---------------------------------------------------------------------------------------------62
3.3.1 Analytical Characterisation and Quantification --------------------------------------62
3.3.1.1 Faradiol Esters--------------------------------------------------------------------------62 3.3.1.2 Catechins---------------------------------------------------------------------------------64 3.3.1.3 Tryptanthrin ----------------------------------------------------------------------------65 3.3.1.4 Cannabinoids ---------------------------------------------------------------------------66
3.3.2 Extraction-------------------------------------------------------------------------------------67
3.3.2.1 Extraction of Faradiol Esters -------------------------------------------------------67 3.3.2.2 Extraction of Catechins ---------------------------------------------------------------68 3.3.2.3 Extraction of Tryptanthrin-----------------------------------------------------------68 3.3.2.4 Extraction of Cannabinoids----------------------------------------------------------68
3.3.3 Foam Fractionation -------------------------------------------------------------------------69
3.3.3.1 Foam Fractionation of Faradiol Esters---------------------------------------------70 3.3.3.2 Foam Fractionation of Catechins ---------------------------------------------------74 3.3.3.3 Foam Fractionation of Tryptanthrin-----------------------------------------------76

4. RESULTS-----------------------------------------------------------------------------------------82 4.1 Accuracy of Measurements and Quantification of Active Principles by HPLC -----82 4.2 Calendula Officinalis------------------------------------------------------------------------------85
4.2.1 Analytical Characterisation of Lupeol Acetate ---------------------------------------85
4.2.1.1 UV-Vis Characterisation -------------------------------------------------------------85
4.2.1.2 HRGC-EI/MS Characterisation -------------------------------------------------------85 4.2.2 Extraction of Faradiol Esters -------------------------------------------------------------86 4.2.3 Enrichment of Faradiol Esters-----------------------------------------------------------87
4.2.3.1 Influence of Surfactant and Additives ---------------------------------------------88 4.2.3.2 Influence of Solute Concentration and pH----------------------------------------89 4.2.3.3 Influence of Height of Foam Tower and Height of Liquid Pool --------------91 4.2.3.4 Influence of Time of Foaming and Gas Flow Rates -----------------------------92 4.2.3.5 Optimised Overall Enrichment Process -------------------------------------------93

4.3 Camellia Sinensis----------------------------------------------------------------------------------95

Contents

______________________________________________________________________________

4.3.1 Analytical Characterisation of Catechins ----------------------------------------------95
4.3.1.1 UV-Vis Characterisation -------------------------------------------------------------95 4.3.1.2 Nuclear Magnetic Resonance Characterisation ---------------------------------96
4.3.2 Extraction of Catechins --------------------------------------------------------------------96 4.3.3 Enrichment of Catechins-------------------------------------------------------------------97
4.3.3.1 Influence of Solute Concentration, Additives and pH ---------------------------98 4.3.3.2 Influence of Consecutive Foaming and Gas Flow Rate----------------------- 100 4.3.3.3 Optimised Overall Enrichment Process ----------------------------------------- 101

Recommended publications
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M

    INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M

    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
  • 18 December 2020 – to Date)

    18 December 2020 – to Date)

    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
  • Are Supplements Supplemented? Evaluating the Composition of Complementary and Alternative Medicines Using Mass Spectrometry and Metabolomics

    Are Supplements Supplemented? Evaluating the Composition of Complementary and Alternative Medicines Using Mass Spectrometry and Metabolomics

    Are supplements supplemented? Evaluating the composition of complementary and alternative medicines using mass spectrometry and metabolomics By Elly Gwyn Crighton BForensics in Forensic Biology & Toxicology (First Class Honours) BSc in Molecular Biology & Biomedical Science This thesis is presented for the degree of Doctor of Philosophy Perth, Western Australia at Murdoch University 2020 Declaration I declare that: i. The thesis is my own account of my research, except where other sources are acknowledged. ii. The extent to which the work of others has been used is clearly stated in each chapter and certified by my supervisors. iii. The thesis contains as its main content, work that has not been previously submitted for a degree at any other university. i Abstract The complementary and alternative medicines (CAM) industry is worth over US$110 billion globally. Products are available to consumers with little medical advice; with many assuming that such products are ‘natural’ and therefore safe. However, with adulterated, contaminated and fraudulent products reported on overseas markets, consumers may be placing their health at risk. Previous studies into product content have reported undeclared plant materials, ingredient substitution, adulteration and contamination. However, no large-scale, independent audit of CAM has been undertaken to demonstrate these problems in Australia. This study aimed to investigate the content and quality of CAM products on the Australian market. 135 products were analysed using a combination of next-generation DNA sequencing and liquid chromatography-mass spectrometry. Nearly 50% of products tested had contamination issues, in terms of DNA, chemical composition or both. 5% of the samples contained undeclared pharmaceuticals.
  • Barbara Lorson

    Barbara Lorson

    COMPARISON OF NEONATAL OUTCOMES IN MATERNAL USERS AND NON-USERS OF HERBAL SUPPLEMENTS A Thesis Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Holly A Larson, B.S. ***** The Ohio State University 2008 Master‟s Examination Committee: Dr. Maureen Geraghty, Advisor Approved by Annette Haban Bartz ______________________________ Dr. Christopher A. Taylor Advisor Graduate Program in Allied Medical Professions COMPARISON OF NEONATAL OUTCOMES IN MATERNAL USERS AND NON-USERS OF HERBAL SUPPLEMENTS By Holly A. Larson, M.S. The Ohio State University, 2008 Dr. Maureen Geraghty, Advisor This pilot study was a retrospective chart review. The purposes of this study were to describe the prevalence herbal supplement use, to identify characteristics linked to increased herbal supplement use and, to identify adverse outcomes linked to herbal supplement use. Rate of use in the study sample of 2136 charts was 1.1% and identified 17 supplements. The most common supplements identified were teas. Characteristics of the neonates and controls were analyzed as appropriate and revealed no statistical significance. Characteristics of the mothers also revealed no statistical difference. There was a statistically significant difference between herbal users and herbal non-users and the trimester prenatal care began. Neonatal outcomes were statistically different on two measures. Further study is needed to be able to make recommendations regarding safety and efficacy of herbal supplements as well as to be able to better understand motives for choosing to use them. ii Dedicated to the Mama and the Daddy Bears iii ACKNOWLEDGMENTS I would like to express my heartfelt gratitude to my advisor, Dr.
  • Auckland Uniservices Limited

    Auckland Uniservices Limited

    Auckland UniServices Limited Legally available, unclassified psychoactive substances and illegal drugs in New Zealand before and after the ban on BZP: a web‐ based survey of patterns of use FINAL REPORT OF FINDINGS June 2009 Janie Sheridan, PhD, BPharm, BA, FRPharmS, RegPharmNZ Rachael Butler, BA, PGDipPH Christine Y. Dong, BSc Hons, BCom Hons Joanne Barnes, PhD, BPharm, MRPharmS, RegPharmNZ, FLS The School of Pharmacy The University of Auckland New Zealand TABLE OF CONTENTS 1 Executive Summary ........................................................................................... 7 2 Introduction .................................................................................................... 11 2.1 Background .............................................................................................. 11 2.1.1 The legislative and regulatory background ................................ 11 2.1.2 The current study ........................................................................ 12 2.2 Study aims ................................................................................................ 12 2.3 Study methods ......................................................................................... 13 2.4 Ethics approval ......................................................................................... 13 2.5 Structure of this report ............................................................................ 13 3 Adverse effects associated with herbal substances used for recreational purposes: a literature review
  • Catalog Stable Isotope Standards for Clinical Mass Spectrometry

    Catalog Stable Isotope Standards for Clinical Mass Spectrometry

    Cambridge Isotope Laboratories, Inc. isotope.com Stable Isotope Standards For Clinical Mass Spectrometry Euriso-Top, Parc des Algorithmes, route de l'orme, 91190 Saint Aubin | France tel: +33 1 69 41 97 98 fax: +33 1 69 41 93 52 +49 (0) 681 99 63 338 (Germany) www.eurisotop.com Ordering Information The CIL Customer Service Department is open from 8:00 a.m. to 5:00 p.m. Eastern Time. Orders may be placed by fax, email or via our website 24 hours a day. Phone: 1.800.322.1174 (North America) +1.978.749.8000 Fax: +1.978.749.2768 Email: [email protected] [email protected] (International) Website: isotope.com Images used are for illustrative purposes only and may not be representative of actual product(s). isotope.com | Stable Isotope Standards for Clinical Mass Spectrometry Welcome Cambridge Isotope Laboratories, Inc. (CIL) is the world leader in the production and distribution of stable isotope-labeled compounds, providing labeled compounds for fields spanning from basic analytical chemistry to modern diagnostics. Over the years, CIL has evolved in its breadth and capacity to both produce and characterize a diverse array of organic compounds to support the development of mass spectrometry (MS) methods. Our ever-expanding product offering has been driven by close customer collaborations and partnerships that we’ve had the privilege of being involved in. It is with great pride that we present CIL’s new “Stable Isotope Standards for Clinical Mass Spectrometry” catalog. This compilation consists of a list of clinically relevant products and a collection of varied content pieces.
  • Antiobesity and Anti-Inflammation Effects of Hakka Stir-Fried Tea Of

    Antiobesity and Anti-Inflammation Effects of Hakka Stir-Fried Tea Of

    food & nutrition research ORIGINAL ARTICLE Antiobesity and anti-inflammation effects of Hakka stir-fried tea of different storage years on high-fat diet-induced obese mice model via activating the AMPK/ACC/CPT1 pathway Qiuhua Li1, Xingfei Lai1, Lingli Sun1, Junxi Cao1, Caijin Ling1, Wenji Zhang1, Limin Xiang1, Ruohong Chen1, Dongli Li2* and Shili Sun1* 1Tea Research Institute, Guangdong Academy of Agricultural Sciences/Guangdong Provincial Key Laboratory of Tea Plant Resources Innovation & Utilization, Guangzhou, China; 2School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China Popular scientific summary • We confirmed that HT treatment significantly reduced body weight and fat accumulation in major organs in high-fat diet-induced obese mice. • The effects of HT appear to be mediated by the activation of AMPK/ACC/CPT-1 pathway and further inhibiting lipogenesis. • Our findings suggest that HT may be used as a potential dietary strategy for preventing obesity and related metabolic disorder diseases. Abstract Background: As a typical representative of metabolic syndrome, obesity is also one of the extremely danger- ous factors of cardiovascular diseases. Thus, the prevention and treatment of obesity has gradually become a global campaign. There have been many reports that green tea is effective in preventing obesity, but as a kind of green tea with regional characteristics, there have been no reports that Hakka stir-fried tea (HT) of different storage years has a weight loss effect. Aims: The aim was to investigate the effect of HT in diet-induced obese mice. Methods: The mice were divided into five groups as follows: the control group received normal diet; the obese model group received high-fat diet; and HT2003, HT2008, and HT2015 groups, after the induction of obesity via a high-fat diet, received HT of different storage years treatment for 6 weeks, respectively.
  • Learning Objectives

    Learning Objectives

    2/26/2019 To help ensure the integrity of competition for Dirty Dozen: High Risk athletes, sports organizations and fans Sport Supplement worldwide. Ingredients Lara Gray, MS, RD, CSSD Senior Director of Education, Board Certified Sports Dietitian 1 Welcome! Learning Objectives Things to note: At the end of the presentation, attendees will 1. It is required by the BOC for Certified Athletic Trainers that you are actively be better able to: present in the live event AND complete the post-webinar survey in order to • Identify dietary ingredients that pose a threat to drug tested athletes. receive your CEU certificate. • Explain how high risk dietary ingredients are being used in sports 2. CEU Statements of Credit (if applicable) supplements. will be emailed to attendees no later than Friday, March 1st. • Analyze sports supplements for high risk dietary ingredients. 3. Please use the “Questions” box in GoToWebinar. Questions will be reviewed by the moderator and answered at the Drug Free Sport International (BOC AP# P8729) is approved by the Board of Certification, Inc. to end. provide continuing education to Athletic Trainers. This program is eligible for a maximum of 1 Category A hour/CEU. ATs should claim only those hours actually spent in the educational program. 4. Download today’s handouts from the “Handouts” tab. 1 2/26/2019 Today: An In-Depth Look 40% - 100% ATHLETES USE SUPPLEMENTS • Type of sport • Level of competition • Definition of supplements Garthe, Ina, and Ronald J. Maughan. "Athletes and Supplements: Prevalence and Perspectives." International journal of sport nutrition and exercise metabolism 28.2 (2018): 126‐138.
  • Qualitative and Quantitative Determination of the Effective Components of the Plants in Different Herbal Slimming Products in Turkey by HPLC

    Qualitative and Quantitative Determination of the Effective Components of the Plants in Different Herbal Slimming Products in Turkey by HPLC

    Turkish Journal of Chemistry Turk J Chem (2019) 43: 825 – 833 http://journals.tubitak.gov.tr/chem/ © TÜBİTAK Research Article doi:10.3906/kim-1711-5 Qualitative and quantitative determination of the effective components of the plants in different herbal slimming products in Turkey by HPLC Benan DURSUNOĞLU1,, Hafize YUCA1,, Sefa GÖZCÜ2,, Bilal YILMAZ3,, Zühal GÜVENALP1;∗, 1Department of Pharmacognosy, Faculty of Pharmacy, Atatürk University, Erzurum, Turkey 2Department of Pharmacognosy, Faculty of Pharmacy, Erzincan University, Erzincan, Turkey 3Department of Analytical Chemistry, Faculty of Pharmacy, Atatürk University, Erzurum, Turkey Received: 02.11.2017 • Accepted/Published Online: 04.03.2019 • Final Version: 11.06.2019 Abstract: Obesity is a serious disease that can be due to genetic and environmental reasons and is defined by the World Health Organization as abnormal or excessive fat accumulation that may impair health. There is an increasing trend towards herbal slimming products in obesity treatment. The quality control analysis of these products is important for public health. In this study, new, simple, and sensitive high performance liquid chromatography methods were developed for qualitative and quantitative determination of arbutin, hydroquinone, ursolic acid, chlorogenic acid, epigallocatechin gallate, epigallocatechin, epicatechin gallate, and catechin in eleven herbal slimming products in Turkey containing Camellia sinensis, Ilex paraguariensis, and Calluna vulgaris. The intra- and interday precisions, stated as the relative standard deviation, were less than 2% and accuracy, based on relative error, was less than 10%. The limits of detection and quantification for arbutin and hydroquinone were 0.80 and 2.40 µg/mL and for the other compounds were0.30 and 0.90 µg/mL, respectively.
  • Plant-Derived Natural Products As Multidrug Resistance Modulators in Cancer Therapy

    Plant-Derived Natural Products As Multidrug Resistance Modulators in Cancer Therapy

    Anatolian Journal of Biology ISSN: 2687-444X 2020 2:1-51 Research Paper Plant-Derived Natural Products as Multidrug Resistance Modulators in Cancer Therapy Mine İsaoğlu 1,*, Medine Güllüce 2 , Mehmet Karadayı 2 1 Institute of Natural and Applied Sciences, Atatürk University, Erzurum, Turkey 2 Faculty of Science, Department of Biology, Atatürk University, Erzurum, Turkey Received 21 December 2020; accepted 30 December 2020 Available online 31 December 2020 Abstract Background: Cancer is the second leading cause of death worldwide and each year tens of millions of people are lost their lives due to different types of cancer. Despite all efforts in the treatment of cancer, the mortality and morbidity rates are still in high levels. Multidrug resistance (MDR) is one of the main impediments in the cancer treatment. MDR might result in tumor metastasis and recurrence, which is responsible for 90% of cancer-related deaths. Many intrinsic and extrinsic factors such as genetic and epigenetic modifications, drug efflux systems, DNA repair mechanisms, apoptotic and autophagic processes contribute drug resistance in cancer cells. To date, various types of molecules have been tested in vitro and in vivo, for MDR modulating activity but there is still no effective anticancer drug to completely overcome MDR. Phytochemicals, in alone or in combination with other chemotherapeutics, are potentially able to sensitize the cancer cells to conventional anticancer drugs in cancer patients with fewer side effects. In this review, we aimed to provide a general perspective about MDR-related mechanisms and novel therapeutic approaches including RNA interference (RNAi) therapy, nanotherapy and cancer stem cell treatments to combat MDR and to highlight the latest MDR reversing agents of plant origin based on their modulating effects on various proteins, enzymes, transcription factors, cell cycle regulators and survival and oncogenic pathways.
  • Mai Muuttunut Piu Miu Miui

    Mai Muuttunut Piu Miu Miui

    MAIMUUTTUNUT US009943513B1 PIU MIU MIUI (12 ) United States Patent ( 10 ) Patent No. : US 9 ,943 ,513 B1 Hughey et al. (45 ) Date of Patent: * Apr . 17 , 2018 (54 ) OPIOID ABUSE DETERRENT DOSAGE (58 ) Field of Classification Search FORMS None See application file for complete search history . (71 ) Applicant : BANNER LIFE SCIENCES LLC , High Point , NC (US ) (56 ) References Cited ( 72 ) Inventors : Justin Hughey , Asheboro , NC (US ) ; U . S . PATENT DOCUMENTS Saujanya Gosangari, Jamestown, NC (US ) ; Chue Hue Yang , Greensboro , NC 4 , 828 ,836 A 5 / 1989 Miller 4 ,861 , 598 A 8 / 1989 Oshlack (US ) 4 , 970 ,075 A 11/ 1990 Oshlack 5 ,266 ,331 A 11/ 1993 Oshlack (73 ) Assignee : BANNER LIFE SCIENCES LLC , 5 , 273 , 760 A 12 / 1993 Oshlack High Point, NC (US ) 5 , 286 ,493 A 2 / 1994 Oshlack 5 ,472 , 943 A 12 / 1995 Crain 5 , 478 , 577 A 12 / 1995 Kaiko ( * ) Notice : Subject to any disclaimer, the term of this 5 , 529 , 787 A 6 / 1996 Ayer patent is extended or adjusted under 35 5 , 549 , 912 A 8 / 1996 Kaiko U . S . C . 154 ( b ) by 0 days. 5 ,656 , 295 A 8 / 1997 Oshlack 5 ,672 , 360 A 9 / 1997 Kaiko This patent is subject to a terminal dis 5 , 702 , 725 A 12 / 1997 Chadha claimer . 5 ,914 ,131 A 6 / 1999 Ayer 5 ,958 , 452 A 9 / 1999 Oshlack ( 21) Appl . No. : 15 /285 ,837 5 , 965 , 161 A 10 / 1999 Oshlack 6 , 228 , 863 B1 5 /2001 Kaiko ( 22 ) Filed : Oct . 5 , 2016 6 , 261, 599 B1 7 / 2001 Huang Related U .
  • Component Analysis of Pu-Erh and Its Anti-Constipation Effects

    Component Analysis of Pu-Erh and Its Anti-Constipation Effects

    MOLECULAR MEDICINE REPORTS 9: 2003-2009, 2014 Component analysis of Pu-erh and its anti-constipation effects GUIJIE LI*, QIANG WANG*, YU QIAN, YALIN ZHOU, RUI WANG and XIN ZHAO Department of Biological and Chemical Engineering, Chongqing University of Education, Chongqing 400067, P.R. China Received June 21, 2013; Accepted February 19, 2014 DOI: 10.3892/mmr.2014.2009 Abstract. The aim of this study was to investigate the effects systems of traditional medicine for the treatment of different of Pu-erh tea on activated carbon-induced constipation in ICR diseases and ailments, however there are a few studies avail- mice. The changes in body weight, dietary intake, gastro- able on the clinical uses of herbs as constipation treatments intestinal transit, first black stool defecation time, number that have demonstrated promising results, particularly Pu-erh and weight of feces, water content of feces and various tea. Pu-erh tea is commonly known as the large leaves of levels of substances in serum were used to evaluate the C. sinensis O. kuntze var. assamica Kitamura, a plant native to anti-constipation effects of Pu-erh tea. Body weight, dietary China (2). Drinking Pu-erh tea for a long period of time is able intake and the amount of water consumed by mice decreased to aid the maintenance of mental and physical health. This tea with activated carbon-induced constipation and those of the is believed to reduce high blood pressure and cholesterol levels, sample treated group mice were higher than the control group and to be important in preventing heart disease and cancer (3).